Research
Hormonal
Dietary restriction (caloric or nutrient restriction) extends lifespan by inactivating the TOR (Target of Rapamycin) pathway, which subsequently influences DAF-16/FOXO activity and mRNA levels.
Dietary restriction, such as caloric restriction, extends lifespan in model organisms by suppressing the TOR pathway. This suppression allows for the activation of DAF-16/FOXO, which regulates genes involved in longevity. This suggests that nutrient sensing is a critical lever for aging.
GoodSupportsHIGH confidence
Various dietary interventions such as caloric restriction (CR) or dietary restriction (DR) may inactivate TOR pathway to promote lifespan extension... TORC1-mediated longevity via the GTPases... is dependent on DAF-16/FOXO.
Why this rating
Supported by multiple citations regarding TOR pathway conservation and interaction with DAF-16.
Source
DAF-16/FOXO Transcription Factor in Aging and Longevity
Xiaojuan Sun et al. · Frontiers in Pharmacology · 2017
DOI 10.3389/fphar.2017.00548
narrative_reviewCited 235×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Inhibition of the Insulin/IGF-1 signaling (IIS) pathway extends lifespan by promoting the nuclear translocation of the DAF-16/FOXO transcription factor, which then activates downstream genes for stress resistance and longevity.Good
- Activation of the AMP-activated protein kinase (AMPK) pathway extends lifespan and stress resistance by directly phosphorylating and activating DAF-16/FOXO.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →